造血干细胞-话题@MedSci

#造血干细胞#

227篇内容 | 7888人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271495, encodeId=4c5e12e149570, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：多种受体酪氨酸激酶信号介导急性血小板减少时的造血干细胞反应, objectType=article, longId=178231, objectId=208f1e823181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208f1e823181, replyNumber=0, likeNumber=82, createdTime=2019-08-28, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208f1e823181, moduleTitle=Blood：多种受体酪氨酸激酶信号介导急性血小板减少时的造血干细胞反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208f1e823181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271494, encodeId=c36412e14945a, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定, objectType=article, longId=177725, objectId=7f3b1e772586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f3b1e772586, replyNumber=0, likeNumber=72, createdTime=2019-08-17, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f3b1e772586, moduleTitle=Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f3b1e772586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271493, encodeId=6a8312e14930f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=SCI TRANS MED：CRISPR-Cas9编辑造血干细胞，助力治疗相关移植, objectType=article, longId=176793, objectId=62aa1e679336, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62aa1e679336, replyNumber=0, likeNumber=57, createdTime=2019-08-05, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62aa1e679336, moduleTitle=SCI TRANS MED：CRISPR-Cas9编辑造血干细胞，助力治疗相关移植, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62aa1e679336)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271492, encodeId=218f12e14924c, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=JAMA：疫苗可有效降低自体造血干细胞移植后带状疱疹发生率, objectType=article, longId=175264, objectId=29bb1e5264d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29bb1e5264d5, replyNumber=0, likeNumber=113, createdTime=2019-07-13, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29bb1e5264d5, moduleTitle=JAMA：疫苗可有效降低自体造血干细胞移植后带状疱疹发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29bb1e5264d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271491, encodeId=80d812e149143, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=《自然》：重大突破！普通胶水破解造血干细胞体外扩增的谜题, objectType=article, longId=168030, objectId=fdca16803091, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdca16803091, replyNumber=0, likeNumber=75, createdTime=2019-06-12, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdca16803091, moduleTitle=《自然》：重大突破！普通胶水破解造血干细胞体外扩增的谜题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdca16803091)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271490, encodeId=5ef212e14909f, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制, objectType=article, longId=167613, objectId=b87a16e61344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b87a16e61344, replyNumber=0, likeNumber=93, createdTime=2019-06-05, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b87a16e61344, moduleTitle=英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b87a16e61344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271489, encodeId=af1212e148935, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法, objectType=article, longId=166721, objectId=b315166e2142, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b315166e2142, replyNumber=0, likeNumber=88, createdTime=2019-05-25, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b315166e2142, moduleTitle=Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b315166e2142)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271488, encodeId=8ac012e1488ff, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=新一代造血干细胞动员剂释倍灵®开出中国首张处方，显著提升非霍奇金淋巴瘤患者移植成功率, objectType=article, longId=164478, objectId=d8c61644e8a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8c61644e8a3, replyNumber=0, likeNumber=78, createdTime=2019-04-19, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8c61644e8a3, moduleTitle=新一代造血干细胞动员剂释倍灵®开出中国首张处方，显著提升非霍奇金淋巴瘤患者移植成功率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8c61644e8a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271487, encodeId=efb112e1487d8, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, objectType=article, longId=164438, objectId=87fe1644385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fe1644385f, replyNumber=0, likeNumber=96, createdTime=2019-04-18, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fe1644385f, moduleTitle=Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fe1644385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271486, encodeId=171e12e148696, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：染色质结合蛋白Phf6可限制造血干细胞自我更新, objectType=article, longId=164290, objectId=28bf164290eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28bf164290eb, replyNumber=0, likeNumber=93, createdTime=2019-04-16, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28bf164290eb, moduleTitle=Blood：染色质结合蛋白Phf6可限制造血干细胞自我更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28bf164290eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271485, encodeId=29c812e148519, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：Asrij/OCIAD1可抑制CSN5介导的p53降解，维持造血干细胞静态, objectType=article, longId=164176, objectId=fcda1641e6a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcda1641e6a6, replyNumber=0, likeNumber=75, createdTime=2019-04-14, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcda1641e6a6, moduleTitle=Blood：Asrij/OCIAD1可抑制CSN5介导的p53降解，维持造血干细胞静态, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcda1641e6a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271484, encodeId=71e012e148479, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：循环血中的肿瘤DNA可用于预测AML/MDS患者造血干细胞移植后的复发风险, objectType=article, longId=163732, objectId=7ea3163e3222, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ea3163e3222, replyNumber=0, likeNumber=82, createdTime=2019-04-08, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ea3163e3222, moduleTitle=Blood：循环血中的肿瘤DNA可用于预测AML/MDS患者造血干细胞移植后的复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ea3163e3222)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271483, encodeId=300712e148392, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=2019 EBMT共识建议：单倍体造血干细胞移植供者的选择, objectType=article, longId=162846, objectId=a92e16284603, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92e16284603, replyNumber=0, likeNumber=30, createdTime=2019-03-25, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92e16284603, moduleTitle=2019 EBMT共识建议：单倍体造血干细胞移植供者的选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92e16284603)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271482, encodeId=3f3712e148285, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：抗CD117抗体可同时清除正常的和异常的造血干细胞！, objectType=article, longId=162489, objectId=d00416248941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d00416248941, replyNumber=0, likeNumber=77, createdTime=2019-03-18, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d00416248941, moduleTitle=Blood：抗CD117抗体可同时清除正常的和异常的造血干细胞！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d00416248941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271481, encodeId=d1e812e148191, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=ECIL-7指南：造血干细胞移植受者的疫苗接种, objectType=article, longId=160689, objectId=6db6160689a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6db6160689a0, replyNumber=0, likeNumber=33, createdTime=2019-02-22, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6db6160689a0, moduleTitle=ECIL-7指南：造血干细胞移植受者的疫苗接种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6db6160689a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271480, encodeId=36cd12e1480fa, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：内皮蛋白C受体（Epcr）可促进造血干细胞植入Mpl缺陷型小鼠并扩增, objectType=article, longId=159656, objectId=8fd115965637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fd115965637, replyNumber=0, likeNumber=82, createdTime=2019-02-10, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fd115965637, moduleTitle=Blood：内皮蛋白C受体（Epcr）可促进造血干细胞植入Mpl缺陷型小鼠并扩增, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fd115965637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271479, encodeId=557112e1479b3, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=造血干细胞移植治疗淋巴瘤中国专家共识（2018版）, objectType=article, longId=159443, objectId=887a15944304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=887a15944304, replyNumber=0, likeNumber=32, createdTime=2019-02-04, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=887a15944304, moduleTitle=造血干细胞移植治疗淋巴瘤中国专家共识（2018版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=887a15944304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271478, encodeId=d5f612e147843, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=Blood：内皮糖蛋白对维持造血干细胞静止至关重要, objectType=article, longId=158679, objectId=ad151586e929, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad151586e929, replyNumber=0, likeNumber=100, createdTime=2019-01-24, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad151586e929, moduleTitle=Blood：内皮糖蛋白对维持造血干细胞静止至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad151586e929)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271477, encodeId=e26712e14775a, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人, objectType=article, longId=155661, objectId=4497155661dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4497155661dc, replyNumber=0, likeNumber=87, createdTime=2018-12-14, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4497155661dc, moduleTitle=J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4497155661dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271476, encodeId=655612e1476d3, content=<a href='/topic/show?id=a0ff950018f' target=_blank style='color:#2F92EE;'>#造血干细胞#</a>, objectTitle=东航被指拒载造血干细胞储运箱客服回复：手续不全, objectType=article, longId=154983, objectId=0d2015498316, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d2015498316, replyNumber=0, likeNumber=84, createdTime=2018-12-04, rootId=0, userName=huanbaofeng, userId=e729101, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d2015498316, moduleTitle=东航被指拒载造血干细胞储运箱客服回复：手续不全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d2015498316)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

造血干细胞

2020-05-29发表于上海

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：多种受体酪氨酸激酶信号介导急性血小板减少时的造血干细胞反应

2019-08-28

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Akari的补体抑制剂Nomacopan治疗小儿造血干细胞移植相关血栓性微血管病，获得FDA快速通道指定

2019-08-17

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

SCI TRANS MED：CRISPR-Cas9编辑造血干细胞，助力治疗相关移植

2019-08-05

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

JAMA：疫苗可有效降低自体造血干细胞移植后带状疱疹发生率

2019-07-13

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

《自然》：重大突破！普通胶水破解造血干细胞体外扩增的谜题

2019-06-12

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

英国NICE推荐将MSD的Prevymis，用于造血干细胞移植后巨细胞病毒的控制

2019-06-05

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Be The Match BioTherapies和Kiadis Pharma宣布战略合作以加速造血干细胞移植疗法

2019-05-25

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

新一代造血干细胞动员剂释倍灵®开出中国首张处方，显著提升非霍奇金淋巴瘤患者移植成功率

2019-04-19

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Lancet haemat：慢病毒造血干细胞基因编辑疗法用于Wiskott-Aldrich综合征患儿的临床疗效和安全性评估

2019-04-18

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：染色质结合蛋白Phf6可限制造血干细胞自我更新

2019-04-16

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：Asrij/OCIAD1可抑制CSN5介导的p53降解，维持造血干细胞静态

2019-04-14

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：循环血中的肿瘤DNA可用于预测AML/MDS患者造血干细胞移植后的复发风险

2019-04-08

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

2019 EBMT共识建议：单倍体造血干细胞移植供者的选择

2019-03-25

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：抗CD117抗体可同时清除正常的和异常的造血干细胞！

2019-03-18

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

ECIL-7指南：造血干细胞移植受者的疫苗接种

2019-02-22

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：内皮蛋白C受体（Epcr）可促进造血干细胞植入Mpl缺陷型小鼠并扩增

2019-02-10

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

造血干细胞移植治疗淋巴瘤中国专家共识（2018版）

2019-02-04

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

Blood：内皮糖蛋白对维持造血干细胞静止至关重要

2019-01-24

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

J Hematol Oncol：套细胞淋巴瘤自体造血干细胞移植后硼替佐米+利妥昔单抗疗效喜人

2018-12-14

huanbaofeng (审核中...)

前往app查看评论内容

#造血干细胞#

东航被指拒载造血干细胞储运箱客服回复：手续不全

2018-12-04

科室
- - 订阅+
  - 更多科室
工具
服务